Growing community of inventors

Annoeullin, France

Patricia Melnyk

Average Co-Inventor Count = 5.54

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 2

Patricia MelnykNicolas Sergeant (7 patents)Patricia MelnykLuc Buee (6 patents)Patricia MelnykPhilippe Verwaerde (4 patents)Patricia MelnykCécilia Estrella (3 patents)Patricia MelnykPascal Carato (3 patents)Patricia MelnykMathieu Barrier (3 patents)Patricia MelnykStéphane Burlet (3 patents)Patricia MelnykAndre Delacourte (2 patents)Patricia MelnykNicolas Le Fur (2 patents)Patricia MelnykMarion Gay (2 patents)Patricia MelnykMarion Donnier-Marechal (2 patents)Patricia MelnykBénédicte Oxombre-Vanteghem (2 patents)Patricia MelnykStephane Burlet (2 patents)Patricia MelnykPatrick Vermersch (2 patents)Patricia MelnykHélène Zephir (1 patent)Patricia MelnykEmilie Nguyen (1 patent)Patricia MelnykNicolas Lefur (1 patent)Patricia MelnykAndré Delacourte (1 patent)Patricia MelnykPascal Carato (0 patent)Patricia MelnykPatricia Melnyk (10 patents)Nicolas SergeantNicolas Sergeant (11 patents)Luc BueeLuc Buee (7 patents)Philippe VerwaerdePhilippe Verwaerde (4 patents)Cécilia EstrellaCécilia Estrella (4 patents)Pascal CaratoPascal Carato (3 patents)Mathieu BarrierMathieu Barrier (3 patents)Stéphane BurletStéphane Burlet (3 patents)Andre DelacourteAndre Delacourte (3 patents)Nicolas Le FurNicolas Le Fur (2 patents)Marion GayMarion Gay (2 patents)Marion Donnier-MarechalMarion Donnier-Marechal (2 patents)Bénédicte Oxombre-VanteghemBénédicte Oxombre-Vanteghem (2 patents)Stephane BurletStephane Burlet (2 patents)Patrick VermerschPatrick Vermersch (2 patents)Hélène ZephirHélène Zephir (2 patents)Emilie NguyenEmilie Nguyen (1 patent)Nicolas LefurNicolas Lefur (1 patent)André DelacourteAndré Delacourte (1 patent)Pascal CaratoPascal Carato (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Institut National De La Sante Et De La Recherche Medicale (7 from 1,743 patents)

2. Université De Lille 2 Droit Et Santé (6 from 13 patents)

3. Alzprotect (4 from 4 patents)

4. Centre Hospitalier Regional Et Universitaire De Lille (chru) (3 from 9 patents)

5. Centre National De La Recherche Scientifique (1 from 5,072 patents)

6. Université Lille 1 - Sciences Et Technologies (1 from 9 patents)

7. Université Lille 2 - Droit Et Santé (1 from 6 patents)

8. Universite Du Droit Et De La Santa-lille Ii (1 from 1 patent)

9. Universite De Lille 2 Droit Et Saute (1 from 1 patent)

10. Université De Lille (55 patents)

11. Inserm (institut National De La Sante Et De La Recherche Medicale) (37 patents)

12. Centre Hospitalier Régional Et Universitaire De Lille (1 patent)

13. Inserm (0 patent)

14. Universite Du Droit Et De La Sante - Lille Ii (0 patent)


10 patents:

1. 10844008 - Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

2. 10807958 - 1,4-bis(3-aminopropyl)piperazine derivative and its use

3. 10772884 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

4. 10537569 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

5. 10179761 - Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

6. 10017476 - 1,4-bis(3-aminopropyl)piperazine derivative and its use

7. 9714245 - Carboline compounds usable in the treatment of neurodegenerative diseases

8. 9562018 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

9. 9044478 - Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

10. 8680095 - Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/11/2025
Loading…